

Claros Diagnostics Announces Issuance of Core U.S. Patent

WOBURN, Mass. -- June 22, 2011 -- Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced that it has received notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the patent “Fluid Delivery System and Method.”

The patent provides broad protection for the use of a storage and delivery method, solving a well-known challenge of microfluidic systems. This critical enabling technology allows the storage of multiple reagents and their automatic delivery with a high degree of control to achieve high performance multiplex assays on the Claros platform. This method has direct applicability in multiple areas of bio-analytical assays including immunoassays, molecular diagnostics, coagulation, hematology and general chemistry. The patent had previously been allowed in Japan, Australia, and Canada, and is in prosecution elsewhere.

Claros has exclusive rights to this patent as well as the “Assay Device and Method” patent allowed in 2010, which “together cover the foundational work in point-of-care assays performed by the founders of the Company,” said Vincent Linder, Ph.D., Claros’ Chief Technical Officer. “Similar to many of the patent applications we have since filed for critical complementary technologies, this specific technology is well suited for any format of bioassays. As such, we are excited to continue to adapt the entire range of clinical assays onto the Claros point-of-care platform.”

About Claros Diagnostics, Inc.

Claros Diagnostics, Inc. is creating innovative products to transition *in vitro* medical diagnostic tests from the laboratory to the point-of-care, such as a physician's office or bedside. Claros is a venture-financed company located in Woburn, MA. www.clarosdx.com

Company Contact:

Claros Diagnostics, Inc.
Michael J. Magliochetti, Ph.D.
781-933-8010

Media Contact:

MacDougall Biomedical Communications
Jennifer Conrad
781-235-3060